Fresenius Kabi and Veritas BI are pleased to officially launch CompoVision, a revolutionary system for Blood Bank Management at Hemo 2011 in Sao Paulo, Brazil.
Based on Veritas BI’s software platform and developed in partnership with Fresenius Kabi, CompoVision integrates all process data of Fresenius blood bank devices, generating information in real time and giving a new and innovative 360° view.
The user friendly interface of CompoVision delivers business critical information for instant decision support, avoiding errors and improving safety for patients and healthcare professionals.
CompoVision provides new insight for blood banks by:
- Providing a 360° holistic overview and decision support
- Integrating processes in the blood bank
- Delivering both real time information and historical analysis of quality processes
- Enabling the anticipation of problems to provide pro-active solutions
- Monitoring key processes to reduce errors
- Empowering users with a friendly and simple interface
Marcia Otta, Marketing & Development Manager at Fresenius Kabi says:
“We are very excited about our partnership with Veritas BI. We believe CompoVision will drive many new innovations in the blood bank industry. Having evaluated different technology platforms, we believe the tools provided by Veritas BI deliver the greatest potential benefits for Fresenius Kabi’s customers here in Latin America. Initial customer feedback to the project has been fantastic, with the first 2 deployments already complete. I am still amazed by how quickly Veritas BI has helped us to deliver these initial projects and look forward to many more projects in 2012.”
Currently, CompoVision is exclusively available for blood banks in Latin America using Fresenius Kabi devices.
About Fresenius Kabi
Fresenius Kabi is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Within I.V. generic drugs, Fresenius Kabi counts among the leading suppliers in the U.S. market.
All over the world more than 22,500 employees are committed to improving the quality of life of critically and chronically ill patients with innovative products for patients in hospitals and outpatients.
